DavidGeorgeMaloneyMD

PubMed

• Development and validation of predictive models of early immune effector cell-associated hematotoxicity (eIPMs).
  Emily C Liang, Jennifer J Huang, Andrew J Portuguese, Valentín Ortiz-Maldonado, Aya Albittar
  Blood Advances. 2024-12-03
• Phase 1 Study of ROR1 Specific CAR T Cells in Advanced Hematopoietic and Epithelial Malignancies.
  Carla A Jaeger-Ruckstuhl, Jennifer M Specht, Jenna M Voutsinas, Hugh R MacMillan, Qian Vicky Wu
  Clinical Cancer Research. 2024-10-28
• 3 citations
  HA-1-targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation.
  Elizabeth F Krakow, Michelle Brault, Corinne Summers, Tanya M Cunningham, Melinda A Biernacki
  Blood. 2024-09-05

Journal Articles

• Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma  
  Parameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica
• Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity After Adoptive Immunotherapy with CD19 CAR-T Cells  
  Mark Wurfel, David G Maloney, Kathleen R Fink, W Conrad Liles, Cameron J Turtle, Cecilia Yeung, Clinical Cancer Research

Abstracts/Posters

• Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase
  David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
  David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
  David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy
  David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T CellsClinically Relevant Abstract
  David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cel...
  David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
  David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressiv...
  David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy
  David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy
  David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Re...
  David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell ...
  David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...
  David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Hit the Ground Running: What You Need to Know About CAR T-Cell Therapy 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lym... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Late Effects of CD19-Targeted CAR-T Cell Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Integrating CAR T-Cell Therapy Into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Stem Cell Transplant and Immunotherapy in Acute Lymphoblastic Leukemia: Foes or Friends? 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all